IntelGenx Technologies Corp., a drug delivery company dedicated to developing oral controlled-release products as well as novel rapidly disintegrating delivery systems, this morning announced financial results for the year ended December 31, 2008.

“2008 was an exciting year for IntelGenx” commented Horst Zerbe, President and Chief Executive Officer of IntelGenx. “In the fourth quarter, the first product involving the company’s proprietary “Versatab” technology, a prenatal vitamin combination was launched under the brand name Gesticare®. We also formed a strategic alliance with DAVA Pharmaceuticals Inc., and completed development of the CPI-300 anti-depressant. In addition, we completed an equity financing and received approval to list our common stock on the TSX Venture Exchange”.

Dr. Zerbe added “The achievements of the last fiscal year should provide a solid foundation in 2009 for our ongoing efforts to build shareholder value. We started to receive royalty payments for the first time with effect from the first quarter of 2009, and are preparing to file an NDA (New Drug Application) for CPI-300.”